Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2019-02-08 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the entry into material definitive agreements related to warrant amendments and exercises, modifications to rights of security holders, and strategic alternatives being evaluated by the company's board. It includes detailed descriptions of securities purchase agreements, warrant exercise agreements, and related financial terms. There are no full financial statements or comprehensive financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy statement, or governance report. It is a regulatory filing reporting material events and agreements that affect the company's capital structure and strategic direction. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (12,158 characters) and detailed content support this classification with high confidence.
2019-02-08 English
HSGX 13G
Major Shareholding Notification
2019-02-04 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 24, 2019, reporting a restructuring plan involving workforce reductions and the departure of certain officers. It includes details about severance agreements and amendments to an executive retention bonus plan. The content focuses on management changes and compensatory arrangements rather than financial results or full reports. The document is not an annual or quarterly report, earnings release, or audit report. It is a current report disclosing management changes and related arrangements, which aligns with the category for announcements of changes in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (11,342 characters) supports it being a substantive filing rather than a brief announcement or certification.
2019-01-24 English
SC 13D/A
Major Shareholding Notification
2019-01-15 English
SC 13D/A
Major Shareholding Notification
2019-01-03 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC by Histogenics Corporation. It primarily discusses a notice from Nasdaq regarding the company's failure to meet the market value requirement for continued listing on The Nasdaq Capital Market, including details about the grace period to regain compliance and potential delisting consequences. The document is an official regulatory filing reporting a material event related to listing compliance but does not contain financial statements or detailed financial performance data. It is not an earnings release, annual or interim report, or audit report. It is also not a report publication announcement since it contains substantive disclosure about the delisting notice and compliance status. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-01-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.